The Texas A&M University System (TAMUS) is the prime contractor for a team of leading academic, non-profit, and commercial institutions that provide the Center’s personnel, infrastructure, products, intellectual property, and commitment to U.S.-based advanced development and manufacturing. The team’s expertise is comprehensive – including early process development, Good Laboratory Practices (GLP), pivotal animal rule efficacy studies, Good Manufacturing Practices (GMP), biomanufacturing, and human clinical trials. All aspects of the program are supported by national leaders in regulatory strategy.
This highly integrated team is pioneering, developing, and utilizing rapid and flexible approaches to shepherd vaccines and therapeutics from proof-of-concept through licensure. Ultimately, the Center will enhance national security by bolstering the United States' response capability to any attack or threat, including (but not limited to) influenza, as well as previously unrecognized, naturally occurring emerging infectious diseases that will broadly impact national and global health.